J&J's Erleada meets in Phase III for non-metastatic CRPC

Johnson & Johnson (NYSE:JNJ) said Erleada apalutamide (JNJ56021927) met the primary endpoint in the Phase III SPARTAN trial to treat non-metastatic castration-resistant prostate cancer (CRPC). Data were presented

Read the full 283 word article

User Sign In